Celsion will begin Phase II trial of ThermoDox later this year

03/1/2010 | American City Business Journals

A Phase II trial of liver cancer treatment ThermoDox will kick off worldwide in the second half of this year, biotech firm Celsion announced. New York's Albert Einstein College of Medicine will participate in the randomized study, which will focus on the efficacy of ThermoDox in treating liver cancer and tumors when combined with radiofrequency therapy.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX